Alpha-Linolenic Acid for Cognitive Decline
What You Need to Know Before You Apply
What is the purpose of this trial?
This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults with mild cognitive impairment and APOE4 genotype. By targeting the endogenous synthesis of docosahexaenoic acid (DHA) through ALA supplementation, the investigators aim to overcome the limitations of direct DHA supplementation, particularly in APOE4 carriers who exhibit low brain DHA levels and impaired blood-brain barrier function. This innovative approach offers a safe, cost-effective, and easily implementable therapeutic strategy for older adults at high risk for Alzheimer's dementia, especially APOE4 carriers, addressing a critical need given the limited cognitive benefits and significant adverse events of current amyloid-clearing drugs in this population.
Who Is on the Research Team?
Michal Beeri, PHD
Principal Investigator
Rutgers University
Are You a Good Fit for This Trial?
This trial is for older adults aged 60+ with mild memory problems (MCI) who carry the APOE4 gene, linked to Alzheimer's. Participants must speak English or Spanish and have someone to report on their daily functioning. They should be able to consent and follow the study plan.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive daily supplementation of 2.6 grams of ALA or placebo for six months
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Alpha-Linolenic Acid
Trial Overview
The trial tests if taking alpha-linolenic acid (ALA), an Omega-3 fatty acid, can help maintain brain health in those at risk of Alzheimer's due to the APOE4 gene. It compares ALA against a placebo in a randomized, double-blind setup.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Participants receive flaxseed oil in 5 mL oral syringes containing 2.6g of ALA, taken daily for six months.
Participants receive corn oil without ALA (iso-caloric placebo) in 5 mL oral syringes that are identical in appearance to those containing ALA, taken daily for six months.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Michal Schnaider Beeri, Ph.D.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.